Dyadic International (NASDAQ:DYAI) Share Price Passes Above Fifty Day Moving Average – Here’s What Happened

Dyadic International Inc. (NASDAQ:DYAI) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.81 and traded as high as $1.34. Dyadic International shares last traded at $1.21, with a volume of 770,602 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Price Performance

The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The company’s fifty day simple moving average is $0.81 and its two-hundred day simple moving average is $0.83. The stock has a market capitalization of $44.09 million, a PE ratio of -5.26 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, sell-side analysts predict that Dyadic International Inc. will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Dyadic International

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Marathon Capital Management raised its holdings in shares of Dyadic International by 142.9% in the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 50,000 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International in the third quarter valued at $190,000. Finally, Geode Capital Management LLC lifted its position in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares in the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.